Manufacturing and Stability Testing of a GNE-Lipoplex for a Clinical Trial for the Treatment of Hereditary Inclusion Body Myopathy Type (HIBM).
Nano-flow 2D-HPLC MALDI-TOF MS/MS for differentially expressed protein analysis in breast cancer patient samples.
Senzer N, Bedell C, Nemunaitis J: OncoVEXGM-CSF: An Oncolytic Viral Immunotherapeutic in Melanoma. Drugs of the Future 2010; 35(6):449.
Phase I Safety and Pharmacokinetic Study of Systemic p53 Gene Therapy (SGT-53) using Immunolipoplexes Targeted by Anti-Transferrin Receptor (TfR) Single Chain Antibody Fragment (scFv):
Development of a Novel, RNAi-Based Therapeutic Targeting Pancreatic Duodenal Homebox-1 (PDX-1) for Insulinoma and Pancreatic Cancer.
Phadke AP, Jay CM, Maples PB, Senzer N, Nemunaitis J, Tong AW. Assessment of pre-clinical safety of GMP grade GNE-lipoplexes after repeat intravenous injections in Balb/c mice. Poster #148. ASGCT 13th Annual Meeting, May 17 – 22, 2010, Washington, D.C.
A Combinatorial Approach for Targeted, Systemic Delivery using Small Molecules and Reversible Masking to Bypass Non-Specific Uptake In Vivo.
A single patient, multiple intravenous (IV) infusion, clinical trial of GNE-lipoplex for therapy of Hereditary Inclusion Body Myopathy (HIBM). Oral #586. ASGCT13th Annual Meeting, May 17 – 22, 2010, Washington, D.C.
Phase I Safety and Pharmacokintetic Study of Systemic p53 Gene Therapy (SGT-53) using Immunopoplexes Targeted by Anti-Transferrin Receptor (TfR) Single Chain Antibody Fragment (scFv)